A Long-Term Multicenter Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole as Maintenance Treatment in Adolescent Patients with Schizophrenia or Child and Adolescent Patients with Bipolar I Disorder
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The reason for this study is to find out the potential benefits and safety of Aripiprazole (Abilify?) in children and adolescents.
Description
The reason for this study is to find out the potential benefits and safety of Aripiprazole (Abilify?) in children and adolescents.
Details
| Condition | Schizophrenia, Bipolar I Disorder |
|---|---|
| Age | 10years - 17years |
| Clinical Study Identifier | TX2349 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.